STK26 and hepatocellular carcinoma: Our study demonstrated a significantly higher frequency of MST4 expression in HCC patients with low clinical stage (stage I-II; 97/208, 47%) than those with high clinical stage (stage III-IV; 30/117, 26%), and in patients with well or moderately differentiated HCC (histological grade 1-2; 60/97, 62%) than those with poorly differentiated HCC (histological grade 3-4; 67/228; 29%) (Figure 1C, 1D and Table 1), implicating MST4 may serve as a prognostic indicator for HCC.